MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Consolidator ... Mass Market Scale-up, Global Reach, Public Capital
Consolidators: BioPharmaceuticals
Johnson & Johnson, Inc. [J&J] (NYSE:JNJ)*
Organization & Developments: Johnson & Johnson (J&J)
*Developments: Johnson & Johnson (J&J)
Parents
Organization & Developments: Johnson & Johnson (J&J)
Children
@JNJNews
*Developments: Johnson & Johnson (Archives 2010 -2015)
*Developments: Johnson & Johnson (Archives 2016 -2017)
*Developments: Johnson & Johnson (Archives 2018 -2020)
*Discharge Decision Support System (D2S2)
*Ethicon division provides surgical systems and instruments.
*Innovation Centers
*Its interventional solutions business provides tools for heart rhythm disorders and neurovascular care.
*Johnson & Johnson (JNJ) division DePuy Synthes houses its orthopedics division (joint reconstruction, spine, sports medicine, and cranio-maxillofacial devices)
*Stelara (ustekinumab)
2021: J&J Reports Vaccine Results
2021: J&J sets out to split the world's largest healthcare conglomerate, hiving off the consumer division
2022: J&J debuts Kenvue as new name for $15B consumer health business spinoff
2022: J&J's Ethicon, CMR Surgical pair up on minimally invasive robotic surgery
2022: J&J's Heart Deal Pumps Up Post-Breakup Prospects_ seekingalpha.com
2022: Johnson & Johnson Goes Back Into Cardiology With A Big Splash_ seekingalpha.com
2022: Johnson & Johnson taps Scottish inspiration in branding its consumer spinoff
2022: Johnson & Johnson: Aspects To Consider After Acquiring Abiomed_ seekingalpha.com
2022: Johnson & Johnson: Steady Growth Play_ seekingalpha
2022: Outlooks Continue To Favor Johnson & Johnson_seekingalpha.com
2023: ASH: J&J, Sanofi square off in newly diagnosed multiple myeloma, with one med showing 'unprecedented' efficacy
2023: Johnson & Johnson MedTech: ‘Stay tuned’ for Ottava next-gen surgical robot
2023: Johnson & Johnson Stock (NYSE:JNJ): Time to Buy the Dip?_www.tipranks.com
2023: Johnson & Johnson: An Update Following The Kenvue IPO_ seekingalpha.com
2023: Johnson & Johnson: Q3 Earnings Unveils Life After Kenvue Spinoff
2023: Johnson & Johnson: Starting To Look Interesting Again_seekingalpha.com
2023: Johnson & Johnson: The Bull Case Can No Longer Be Ignored
2024: 4 Positives For Johnson & Johnson
2024: 6 ways Johnson & Johnson is using AI to help advance healthcare
2024: As urged by the AHA and others, J&J tells HRSA it is abandoning proposed 340B rebate plan
2024: Decoding Johnson & Johnson (JNJ): A Strategic SWOT ..
2024: DLA_Johnson & Johnson Health Care Systems Inc., awarded a maximum $86,115,042 fixed-price, indefinite-delivery/indefinite-quantity contract for joint orthopedic procedural packages and supplies.
2024: Growth Prospects Enhanced by Key Acquisitions and Approvals
2024: Is Johnson & Johnson (NYSE:JNJ) a Worthwhile Dividend Stock? _ www.tipranks.com
2024: J&J Scraps Pipeline Assets Including Alzheimer’s and Parkinson’s Candidates
2024: J&J’s Ottava surgical robot to begin clinical trial after FDA nod
2024: Johnson & Johnson 2023 Q4 - Results - Earnings Call Presentation
2024: Johnson & Johnson 2024: Above-market growth continues
2024: Johnson & Johnson Announces Collaborative Effort with USAID to Strengthen the Health Workforce Across Latin America and the Caribbean
2024: Johnson & Johnson Q3: Strengthening Cardiovascular Device Portfolio
2024: Johnson & Johnson revenue 2005-2023
2024: Johnson & Johnson: $2 Billion Buyout Of Antibody Drug Conjugate Specialist Ambrx Is Good Business_ seekingalpha.com
2024: Johnson & Johnson: A High-Quality Dividend King Facing Furious Headwinds
2024: Johnson & Johnson: Balance Growth Between MedTech And Medicine, Initiate With A 'Buy'
2024: Johnson & Johnson: Buy This Bargain Before It's Gone
2024: Johnson & Johnson: Dividend Legend At A Discount
2024: Johnson & Johnson: One Of The World's Safest Stocks Could Return +10% Per Year_ seekingalpha.com
2024: Johnson & Johnson: Policy Uncertainty Elevated, But Shares Remain Inexpensiveseekingalpha.com
2024: Johnson & Johnson: Positioned To Receive Benefits Of Heavy R&D Investments
2024: Johnson & Johnson: Remaining A Buy Despite Remaining Risks
2024: Johnson & Johnson: Self-Proclaimed 'Dividend King' Faces Tricky Outlook
2024: Johnson & Johnson: The Dividend King Is Back
2024: Johnson & Johnson: Tracking Well Above The Industry
2024: Johnson & Johnson: Wait For More Clarity (Rating Downgrade)
2024: Johnson & Johnson: You Need To Look At This Chart (Rating Upgrade)
2024: Johnson & Johnson's (NYSE:JNJ) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
2024: Johnson & Johnson's Acquisition Of Ambrx Biopharma: Hold Through It_ seekingalpha.com
2024: Johnson & Johnson's Bullish Outlook: Surprising Strength You Shouldn't Overlook_ seekingalpha.com
2024: Johnson & Johnson’s new robotic surgical system to rival Intuitive Surgical’s da Vinci
2024: Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113) in Plaque Psoriasis, a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor
2024: With 73% ownership of the shares, Johnson & Johnson (NYSE:JNJ) is heavily dominated by institutional owners
2025: Johnson & Johnson Could Serve As High-Yield Bond Alternative
2025: Johnson & Johnson MedTech completes first cases with Ottava surgical robot
2025: Johnson & Johnson: No More Tears, Just Gains In Intra-Cellular Acquisition
2025: Johnson & Johnson: Rich History Of Excellence Poised To Endure_seekingalpha.com
2025: Kenvue + Johnson & Johnson: I Choose To Own The Whole 'Humpty Dumpty'
2025: What Johnson & Johnson Is Getting With The Acquisition Of Intra-Cellular Therapies
Jumps
*Organization: Johnson & Johnson (J&J)